ES2559857T3 - Nuevos inhibidores de galactósido de galectinas - Google Patents

Nuevos inhibidores de galactósido de galectinas Download PDF

Info

Publication number
ES2559857T3
ES2559857T3 ES13700935.3T ES13700935T ES2559857T3 ES 2559857 T3 ES2559857 T3 ES 2559857T3 ES 13700935 T ES13700935 T ES 13700935T ES 2559857 T3 ES2559857 T3 ES 2559857T3
Authority
ES
Spain
Prior art keywords
optionally substituted
groups
group
independently selected
galectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13700935.3T
Other languages
English (en)
Inventor
Ulf Nilsson
Hakon Leffler
Balaram Mukhopadhyay
Vishal Rajput
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galecto Biotech AB
Original Assignee
Galecto Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galecto Biotech AB filed Critical Galecto Biotech AB
Application granted granted Critical
Publication of ES2559857T3 publication Critical patent/ES2559857T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Un compuesto de la Fórmula general ( I): **Fórmula** en donde: R1, R2, R3, R4 y R5 son independientemente seleccionados del grupo que consiste en hidrógeno, grupos alquilo opcionalmente sustituidos, halógenos, grupos alcoxi opcionalmente sustituidos, grupo hidroxilo, grupos carbonilo sustituidos, grupos aciloxi opcionalmente sustituidos, y grupos amino opcionalmente sustituidos, o en donde dos, tres, cuatro o cinco de R1, R2, R3, R4 y R5 en posiciones adyacentes pueden unirse para formar uno o más anillos, en donde el resto de R1, R2, R3, R4 y R5 es/son independientemente seleccionados del grupo anterior.
ES13700935.3T 2012-01-25 2013-01-24 Nuevos inhibidores de galactósido de galectinas Active ES2559857T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12152413.6A EP2620443A1 (en) 2012-01-25 2012-01-25 Novel galactoside inhibitors of galectins
EP12152413 2012-01-25
PCT/EP2013/051339 WO2013110704A1 (en) 2012-01-25 2013-01-24 Novel galactoside inhibitors of galectins

Publications (1)

Publication Number Publication Date
ES2559857T3 true ES2559857T3 (es) 2016-02-16

Family

ID=47598867

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13700935.3T Active ES2559857T3 (es) 2012-01-25 2013-01-24 Nuevos inhibidores de galactósido de galectinas

Country Status (8)

Country Link
US (1) US9353141B2 (es)
EP (2) EP2620443A1 (es)
JP (1) JP6158840B2 (es)
CN (1) CN104066743B (es)
CA (1) CA2854986C (es)
ES (1) ES2559857T3 (es)
IN (1) IN2014DN05772A (es)
WO (1) WO2013110704A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070089259A (ko) 1999-11-03 2007-08-30 브리스톨-마이어스스퀴브컴파니 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
JP6366598B2 (ja) * 2012-11-15 2018-08-01 タフツ ユニバーシティー ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット
JP2016507503A (ja) 2012-12-20 2016-03-10 ヘンリー フォード ヘルス システム ガレクチン−３を阻害することによる拡張期心不全を治療する方法
EP3166956B1 (en) * 2014-07-09 2020-03-18 Galecto Biotech AB Novel hybrid galactoside inhibitor of galectins
WO2016120403A1 (en) * 2015-01-30 2016-08-04 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
WO2017152048A1 (en) * 2016-03-04 2017-09-08 Galectin Sciences, Llc Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
EP3484903A1 (en) * 2016-07-12 2019-05-22 Galecto Biotech AB Alpha-d-galactoside inhibitors of galectins
CA3025867A1 (en) * 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
US11576924B2 (en) 2017-05-12 2023-02-14 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
EP3732186A1 (en) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
WO2020002765A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
CA3122321A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
EP2679595B1 (en) 2008-05-16 2016-12-28 Galecto Biotech AB Di-(3-deoxy-3-1H-1,2,3-triazol-1-yl)-beta-D-galacto-pyranosyl)sulfane derivatives as galectin-3 inhibitors
WO2010126435A1 (en) 2009-04-28 2010-11-04 Forskarpatent I Syd Ab Novel galactoside inhibitors of galectins
ES2817888T3 (es) 2012-10-31 2021-04-08 Galecto Biotech Ab Inhibidor de galactósido de galectina-3 y su uso para tratar fibrosis pulmonar

Also Published As

Publication number Publication date
EP2807176B1 (en) 2015-12-30
EP2807176A1 (en) 2014-12-03
WO2013110704A1 (en) 2013-08-01
US20140336146A1 (en) 2014-11-13
CN104066743A (zh) 2014-09-24
CA2854986A1 (en) 2013-08-01
CN104066743B (zh) 2016-04-06
US9353141B2 (en) 2016-05-31
IN2014DN05772A (es) 2015-04-10
CA2854986C (en) 2019-09-17
JP2015504909A (ja) 2015-02-16
EP2620443A1 (en) 2013-07-31
JP6158840B2 (ja) 2017-07-05

Similar Documents

Publication Publication Date Title
ES2559857T3 (es) Nuevos inhibidores de galactósido de galectinas
CR20150447A (es) Nuevos derivados de pirazol
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
ECSP13013074A (es) Nuevos derivados de piridina
CR20150018A (es) Inhibidores macrocíclicos de virus flaviviridae
CR20150250A (es) Nuevos derivados de piridina
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CR20150085A (es) Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
EA201890239A3 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
UY34822A (es) Composiciones y métodos para silenciar la expresión genética
CR20150204A (es) Nuevos derivados de piridina
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY34414A (es) Composiciones hemostáticas
ECSP12012103A (es) Inhibidores de virus flaviviridae.
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
CR20150061A (es) Compuesto de pirazolopirimidinas
UY35447A (es) Moduladores de p2x7
UY34057A (es) Inhibidores del virus de la hepatitis c
CR20150440A (es) Nuevos derivados de piridina
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
UY35410A (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
CR20150511A (es) Nuevos derivados de purina